[February 09, 2016]

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2015 - 78 Companies & Drug Profiles - Research and Markets

Research and Markets (http://www.researchandmarkets.com/research/b9w4xd/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview
3. Therapeutics Development
4. Pipelin Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Overview
5. Pipeline Products for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis
6. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies
7. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes
8. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies
13. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes
14. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development

• Absynth Biologics Limited
• Adenium Biotech ApS
• AIMM Therapeutics B.V.
• Alchemia Limited
• Allergan Plc
• AlphaMab Co., Ltd
• Alvogen Korea
• AmpliPhi Biosciences Corporation
• AnGes MG, Inc.
• Aphios Corporation
• AstraZeneca Plc
• Aurigene Discovery Technologies Limited
• Bharat Biotech International Limited
• BioDiem Ltd
• BioSource Pharm, Inc.
• C3 (News - Alert) Jian, Inc
• Cellceutix Corporation
• Cempra, Inc.
• ContraFect Corporation
• CrystalGenomics, Inc.
• CSA Biotechnologies LLC
• Debiopharm International S.A.
• DesignMedix, Inc.
• Destiny Pharma Limited
• Dong-A Socio Group
• Ensol Biosciences Inc.
• Excelimmune, Inc.
• Galapagos NV
• GangaGen Inc.
• Helix BioMedix, Inc.
• Hsiri Therapeutics, LLC
• Ildong Pharmaceutical Co., Ltd.
• Immupharma Plc
• ImmuVen, Inc.
• iNtRON Biotechnology Inc.

For more information visit http://www.researchandmarkets.com/research/b9w4xd/methicillinresist

View source version on businesswire.com: http://www.businesswire.com/news/home/20160209006524/en/

[ Back To TMCnet.com's Homepage ]